Vidarabine (adenine arabinoside) is a purine nucleoside useful in humans for therapy of herpes simplex virus encephalitis and herpes zoster virus infections in immunocompromised patients. However, the potential usefulness of vidaribine is limited by its poor solubility, which requires continuous infusion in relatively large volumes of intravenous fluid. Vidarabine 5'-monophosphate is highly soluble and has the advantage that it can be administered intermittently intramuscularly or intravenously. In a clinical, pharmacokinetic study, plasma levels and urinary excretion of vidarabine 5'-monophosphate were determined after intravenous and intramuscular administration in 29 immunosuppressed patients with herpes simplex or zoster virus infections at dosages of 15 to 30 mg/kg per day administered for 5 days. As determined by high-pressure liquid chromatography, vidarabine 5'-monophosphate was metabolized in a fashion comparable to the metabolism of vidarabine and its major metabolite in plasma was arabinosyl hypoxanthine. After administration, 40 to 50% of the vidarabine 5'-monophosphate was recovered from the urine as arabinosyl hypoxanthine, and 3 to 4% was recovered as vidarabine. Determinations of areas under the curve for arabinosyl hypoxanthine were not statistically different by dosage for intramuscular or intravenous routes of administration. At all dosages studied, viral clearance appeared to occur with therapy. The advantage of increased solubility will lead to controlled clinical investigations in which vidarabine 5'-monophosphate is administered by intramuscular or intravenous routes against targeted human herpesvirus infections.
Vidarabine (adenine arabinoside) is a purine nucleoside useful in humans for therapy of herpes simplex virus encephalitis and herpes zoster virus infections in immunocompromised patients. However, the potential usefulness of vidaribine is limited by its poor solubility, which requires continuous infusion in relatively large volumes of intravenous fluid. Vidarabine 5'-monophosphate is highly soluble and has the advantage that it can be administered intermittently intramuscularly or intravenously. In a clinical, pharmacokinetic study, plasma levels and urinary excretion of vidarabine 5'-monophosphate were determined after intravenous and intramuscular administration in 29 immunosuppressed patients with herpes simplex or zoster virus infections at dosages of 15 to 30 mg/kg per day administered for 5 days. As determined by high-pressure liquid chromatography, vidarabine 5'-monophosphate was metabolized in a fashion comparable to the metabolism of vidarabine and its major metabolite in plasma was arabinosyl hypoxanthine. After administration, 40 to 50% of the vidarabine 5'-monophosphate was recovered from the urine as arabinosyl hypoxanthine, and 3 to 4% was recovered as vidarabine. Determinations of areas under the curve for arabinosyl hypoxanthine were not statistically different by dosage for intramuscular or intravenous routes of administration. At all dosages studied, viral clearance appeared to occur with therapy. The advantage of increased solubility will lead to controlled clinical investigations in which vidarabine 5'-monophosphate is administered by intramuscular or intravenous routes against targeted human herpesvirus infections.
The development of vidarabine (vira-A) as an antiviral agent has stimulated the introduction of promising compounds for clinical evaluation. As new therapeutic agents are developed, pharmacokinetic and tolerance studies must precede drug efficacy evaluations. Ideally, these studies can provide information regarding the optimal route of drug administration, plasma levels at defined dosages, half-life, metabolism, clearance, and degree of penetration into cerebrospinal fluid. In addition, preliminary data regarding viral clearance and toxicity are obtained.
An orderly approach to the study of antiviral agents has been followed in the development of vira-A for clinical evaluation (6, 9) . vira-A is a purine nucleoside which, when given intravenously, is deaminated to arabinosyl hypoxanthine (ara-Hx), and this latter compound is the principle metabolite in plasma and urine (2, 3) . Because of both poor solubility and intramuscular absorption, vira-A requires large fluid volumes for intravenous administration and therefore must be given over prolonged periods (8 to 12 h). In herpes simplex virus encephalitis, obligate fluid load may prejudice patient care.
The phosphorylated ester of vira-A, vidarabine 5'-monophosphate (vira-MP), is water soluble and consequently may be a potentially more useful antiviral agent. The in vitro inhibitory activity of this drug against the herpesviruses is similar to that of vira-A (8). The halflife after single-dose administration of radioactively labeled vira-MP is 3.5 to 6.2 h and this drug is metabolized to ara-Hx (A. J. Glazko, personal communication). Because tolerance and detailed pharmacokinetics were not ascertained in this early study, we performed a doseescalating, pharmacokinetic, tolerance, uncontrolled virological study of vira-MP in humans after administration of this drug by intramuscular and intravenous routes. Toxicity monitoring. Physicians examined patients daily for evidence of adverse reactions to the drug, including pain at the injection site, nausea, vomiting, diarrhea, and central nervous system dysfunction. Serial blood and urine specimens were obtained at the time of enrollment, on days 3 and 7, and then weekly for 1 month to monitor for laboratory toxicity. Complete blood counts with differential, platelets, reticulocyte count, and assessments of liver and renal function were performed. In addition to the previously documented evaluations, weekly weights were determined. Creatinine clearance and estimated renal plasma flow as determined by radionucleotide scanning were recorded for all patients before and after therapy.
MATERIALS AND METHODS

RESULTS
Study population. A total of 29 patients entered the study, and pharmacokinetic, drug tolerance, and viral clearance data were obtained for all; 13 patients were renal transplant recipients, and the remaining 16 were immunosuppressed by drugs or underlying diseases. In the latter group, seven had lymphoproliferative malignancies, six had solid tumors, and the remaining three were receiving high doses of corticosteroids for other conditions. A total of 21 patients had varicella-zoster virus infections (8 disseminated and 13 localized), and 8 patients had progressive mucocutaneous herpes simplex virus infections.
Pharmacokinetic assessment. The major metabolite of vira-MP in plasma was the hypoxanthine derivative ara-Hx; vira-MP was not detected in plasma or urine specimens. In Fig. 1 plasma levels of ara-Hx are plotted against time for all doses studied. The half-life of ara-Hx ranged from 2.3 to 5.4 h (mean ± standard error of the mean, 3 .98 ± 1.9 h) after intravenous administration of vira-MP. Peak plasma levels were achieved 0.5 and 3 h after intravenous and intramuscular administrations, respectively. When found in plasma, vira-A was present at low concentrations, averaging 1.0 ,ug/ml regardless of dose. There was no statistically significant difference between mean intravenous and intramuscular plasma levels for either vira-A or araHx at any dose studied. In addition, no statistical difference existed for grand mean AUC determinations for route of administration at each dosage. After intravenous administration 88 of 234 specimens (33%) had detectable vira-A levels, in contrast to 112 of 330 (34%) after intramuscular administration. Plasma levels versus renal function. In renal transplant recipients, both mean plasma levels and AUC determinations at all doses did not differ significantly from levels obtained in study patients with other underlying conditions. Renal function remained stable during the treatment period in both groups, with the exception of three individuals. Two of these three were renal transplant recipients who had increasing serum creatinine levels and both decreasing creatinine clearance and estimated renal plasma flow evaluations during the study period, which were attributed to graft rejection. Both received vira-MP intramuscularly at 30 mg/kg per day, resulting in mean peak plasma ara-Hx levels of 14.4 and 14.8 ,ug/ml. The third patient received 25 mg/kg per day intravenously and had a mean peak plasma level of 19.2 ,ug/ml. Both peak plasma levels and AUC determinations exceeded by twofold or more mean levels achieved for the dosage group. All three patients had creatinine clearances equal to or less than 50 ml/min per 1.73 m2 and estimated renal plasma flows of 150 to 240 ml/min. In contrast, the remaining 26 patients had creatinine clearances in excess of 90 ml/min per 1.73 M2. Thus, patients with seriously impaired renal function had higher plasma and AUC levels of ara-Hx.
Clinical and virological assessment. At all dosages studied, the 21 patients with zoster cleared the virus from lesions rapidly after enrollment into the study regardless of the dosage utilized. As Fig. 2 shows, more than 50% of these patients became virus negative and remained so after 2 days of medication. Time to cessation of new vesicle formation and total pustulation paralleled viral clearance. The duration of disease before therapy was 6.3 ± 1.2 days (mean ± standard error of the mean). Figure 3 shows the quantitative reduction in herpes simplex virus excretion from lesion sites. At all doses studied, a reduction in viral excretion occurred with drug administration; this was particularly so at dosages of 25 and 30 mg/kg per day. As observed in prior studies (1), viral excretion returned in four of eight renal transplant patients approximately 10 days after therapy. Presumably, this is a reflection of persistently impaired host defense.
Cutaneous healing was paralleled in all cases by clinical improvement (loss of pain, progressive scabbing, and complete cutaneous re-epithelialization). Progression one) associated with drug administration, and these patients had mean peak plasma ara-Hx concentrations of 14.4 to 19.2 Ag/ml, well above the mean values for patients receiving the same dosages. All had abnormal renal function throughout the study period; two were renal transplant recipients and received the drug intramuscularly, whereas the third received the drug intravenously.
-On weekly follow-up, no evidence of late toxicity appeared. Two patients died after the study, one from massive pulmonary emboli unrelated to drug administration and the other from squamous cell carcinoma of the lungs. In both patients ara-Hx levels were the same as the levels in patients treated with equivalent dosages.
(ii) Laboratory toxicity. Two patients had more than a 20% reduction from base line of hematocrit. Gastrointestinal bleeding and hemolysis were not found in either patient. One patient became leukopenic during therapy, which was attributed to recent cytoxan therapy. Elevations of serum glutamic oxaloacetic transaminase (SGOT) levels occurred in seven patients (24%) who received vira-MP. In five, the elevation was twice base line, whereas in two there was a fivefold SGOT elevation during therapy. Five of the seven patients received drug intramuscularly, and four had elevated creatinine phosphokinase levels (MM band). All SGOT abnornalities returned to base line within 2 weeks after completion of the study.
DISCUSSION
Vira-MP appears to offer a significant advantage over vira-A for therapy of herpesvirus infections in humans. Continuous infusion of the pooly soluble parent compound, vira-A, is both complicated in critically ill patients and requires large volumes of intravenous fluid for adequate drug delivery. vira-MP may provide an alternative drug for therapy of life-threatening herpesvirus infections in humans if efficacy can be confirmed in controlled investigations. The present study demonstrates that the pharmacokinetics and metabolism of vira-MP are similar to those of the parent compound. Specifically, the principal metabolite detectable in plasma and urine after drug administration is ara-Hx, with small amounts of vira-A present, as demonstrated by high-pressure liquid chromatography. When the total numbers of specimens with detectable vira-A after intravenous and intramuscular administrations are compared, the frequency distribution does not favor one route over the other. Similarly, when AUC determinations of plasma levels of ara-Hx are compared for both routes, there is no significant difference. Buchanan, personal communication) .
After parenteral administration of vira-MP, drug excretion is similar to the excretion observed after administration of the parent compound, vira-A. For both drugs, the principal route of clearance is via the kidneys, and both vira-A and ara-Hx are recovered in the urine.
VOL. 18, 1980 Nearly 45% of the administered drug is recovered as ara-Hx, and approximately 5% is recovered as vira-A. Excretion after intravenous dosing is somewhat cretion after intravenous dosing is somewhat greater for all dosages studied. Not all of drug administered is quantitatively recovered in the urine. This discrepancy varies between 40 and 60% according to the individual patient. From prior studies with vira-A, it is apparent that the drug can be further metabolized from ara-Hx to hypoxanthine, which is excreted in the urine and cannot be quantitated by this assay (2) . Preliminary unpublished data suggest that the same phenomenon occurs after the administration of vira-MP (Buchanan, personal communication) . The inability to recover all of the drug places limitations on pharinacokinetic interpretations.
At all dosages of vira-MP studied, viral clearance and resolution of clinical disease appeared to occur with therapy; however, efficacy cannot be determined by a study of this design. As noted previously with vira-A therapy, administration of vira-MP does not result in plasma levels of vira-A or ara-Hx which inhibit viral replication in vitro (8) . The intracellular concentrations of the drug and metabolites would have to be determined to resolve this discrepancy.
Of special importance in regard to the potential use of vira-MP for herpesvirus infections of the central nervous system is penetration of the drug across the blood-brain barrier. In this study four patients had documented cerebrospinal fluid levels of ara-Hx very similar to those obtained after the administration of vira-A (1). These cerebrospinal fluid levels were approximately two-thirds of the simultaneously determined plasma level.
When plasma levels of ara-Hx were compared in renal transplant recipients and patients with other diseases, no significant difference was present for mean peak levels at any dose. However, when patients were evaluated according to renal function, irrespective of underlying medical conditions, elevated plasma levels of ara-Hx were found in those individuals with deteriorating or poor renal function (creatinine clearance, c50 ml/min per 1.73 m2). Of the three patients with decreased creatinine clearances and estimated renal plasma flows, all had peak ara-Hx and AUC levels well in excess of those found in other patients studied at the same dosage. It was these three patients who had evidence of neurological abnormalities, which were possibly related to vira-MP administration. A similar adverse experience has been noted with vira-A therapy of patients with chronic hepatitis B infections (4). However, all three patients had other medical complications, such as cytomegaloviremia and pneumonia in one, multiple pulmonary emboli with hypoxemia and tuberous sclerosis in another, and end-stage metastatic carcinoma with C02 narcosis in the third. Similar neurological toxicity has been observed for inexplicable reasons with extremely high doses of vira-A administered intramuscularly to rhesus monkeys (4). Thus, caution must be exercised when employing either vira-A or vira-MP in patients whose renal function is marginal or deteriorating. In these studies renal function warranting caution was a creatinine clearance of less than 50 ml/ min per 1.73 m2 or an estimated renal plasma flow of less than 300 ml/min or both.
The major laboratory abnormality associated with vira-MP administration appears to be elevation of SGOT levels. As expected, this abnormality was most evident after intramuscular administration of the drug (17%), but it was also observed infrequently after intravenous administration (7%). Tissue breakdown at the injection site probably accounted for the higher frequency of SGOT elevations in patients who received the drug intramuscularly. All abnormalities resolved spontaneously within 2 weeks after the last dose of drug.
Vira-MP represents a new and potentially useful antiviral agent. The studies performed to date have shown that this drug appears to be relatively nontoxic and can be administered both intravenously and intramuscularly at dosages of up to 25 mg/kg per day. There is no evidence from the present study of progressive drug accumulation. As with vira-A, vira-MP and its metabolites are rapidly cleared by the kidneys. Based upon the knowledge gained from pharmacological studies of the parent compound, vira-A, supplemented by single-dose radioactive studies, vira 
